Responsible for making major corporate decisions, managing overall operations, and setting the company's strategic direction. Oversee employment decisions at the executive level of the company. Lead a team of executives to consider major decisions including acquisitions, mergers, joint ventures, or large-scale expansion.

An innovative dental technology that combines the benefits of an antimicrobial and regenerative medicine to treat variety of oral and bone-related conditions, starting with initial indication for periodontitis. Breakthrough, patented technology that can prevent and/or eliminate need for surgery. OralBiolife studies have demonstrated regeneration (%) measured the distance between the bone line and a tooth reference. Calculated as a ratio before/after treatment. The results are astounding! After one month of therapy, PiezoGEL showed a significant reduction in the exposed dental roots compared to the clinical standard. • Platform Technology: The antimicrobial and bone-regenerating technology can be applied to many applications that require a sterile, high-quality seal with bone, including dental and orthopedic implants. The remineralization activity can be applied to dental sealants and composite restorations.https://www.oralbiolife.com/

Kaida Biopharma is at the forefront of revolutionizing the fight against ovarian and women’s cancers with our KAD 101 and KAD 102 leading assets. Based on a groundbreaking research of G129R, it can potentially significantly enhance current treatment efficacy. The innovative approach combines cutting-edge research and technology to address critical unmet medical needs, striving to improve patient outcomes and elevate quality of life. With a steadfast commitment to scientific excellence and collaborative efforts, Kaida is transforming cancer care and empowering women in their battle against these formidable challenges. For more information, visit Kaida Biopharma.

Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life sciences.

Transforming Potential into Success: Building, Turning Around, and Restructuring CompaniesWe specialize in optimizing your company’s potential by providing expert guidance for startups, universities, and incubator communities. Our services include developing foundational strategies, designing spin-out approaches, establishing funding pathways, and identifying and executing strategic partnerships. We also accelerate asset approval processes to help you achieve your goals efficiently.Stella Vnook has built a highly skilled team of CEOs, COOs, and CSOs who offer advisory support or fractional C-suite services tailored to your needs.As an experienced biopharmaceutical executive with over 20 years of leadership, Stella has driven transformational change across global portfolios, from early-stage R&D to commercialization. A serial founder and C-suite leader, she brings deep expertise in healthcare economics and market access strategies, positioning products for patients, providers, and payers.Her proven track record spans creating value for startups and managing large-scale portfolios, including building companies from the molecule up and steering diverse portfolios at Top 3 pharmaceutical firms. Stella ensures every venture is positioned for success in an evolving industry landscape.Full list of recent companies available upon request: ORAL BIOLIFE FounderGEI & CorriXR (6/21 - 4/31/24) - strategy/ fund raisingLIKARDA - hydrogel encapsulation technology (2023 - current)TheraPallet (2022) & VitalTE (2023 - Current) - hormone replacement company and AI tech for precision medicine https://www.vitaltelife.com/https://therapellet.com/Brainstorm UPENN (2023 - Current) - https://brainstormdx.com/Kaida Pharma (2024 - Current) Ovarian Cancer - Women's health NewCo https://www.kaida-biopharma.com/

Development-stage biotech company, focused on cancer, rare diseases, diabetes and cardiovascular conditions.

NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand‘ memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity.

Our Mission is to become an industry leader in Cell Therapy Development along with evolving and innovative treatment options starting with Type 1 Diabetes and evolving to treat sub-set of patients with Type 2. MaiCell seeks to utilize its unique patented xenotransplantation technology of islet-cells, to develop effective treatments for Diabetes Mellitus (DM).The key treatment objectives are:- Increase the insulin production in pancreas to stabilize the disease. - Demonstrate significant deceleration of disease progression. - Show significant reduction in insulin intake and decrease in HbA1c for extended period of time.

Diverse Biotech, Inc. is an innovative, clinical-stage bio-pharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary and patented CUSP(tm) technology platform in cancer research. Diverse Biotech is focused on medical discoveries and the development of new molecules for the treatment of Oncology and other debilitating diseases.

The Vice President of Managed Markets & Trade is responsible for the development, implementation and execution of all managed care strategies across the entire portfolio, supporting upcoming launches and Business Development assessment. The US healthcare landscape is highly complex and with the enactment of the Affordable Care Act Legislation and proposed revisions, the healthcare systems segment has only become more complex and dynamic. Accountable for MM Strategy, Sales, contract operations, channel strategy, contract analytics, pricing, reimbursement, GTN and distribution channels.

This position reached beyond the traditional VP of marketing and strategy role. This position allowed me to combine my passion for marketing, strategy and sales with my experience of building effective teams and expand it globally. Starting with launching NEW RP Scherer Softgel brand —the leading delivery technology provider in target customers and markets, we drove sales execution with new targeting techniques, market segmentation, expert marketing, sales aids, customer presentations and training.We maximized revenue growth by focusing marketing strategy on global and emerging markets; expanded Global RP Scherer Softgel brand into European market, China and LATAM.Accelerated growth through technology and new product innovation by launching five pharmaceutical franchises, two consumer/ cosmetics franchises, and established a robust technology platform consisting of seven new branded technologies for Softgel, with three additional technologies pending to be branded. Established revenue driven product management: provided marketing leadership in all targeted franchises, enabling Softgel to meet its financial commitments for revenue and EBITDA in FY 2013.

Responsible for characterizing future opportunities for the Company by leading cross-functional teams to develop key capabilities allowing the U.S. Commercial team to optimize our business 3-5 years in the future.

Lead the strategy and execution of new division within Merck Marketing & Sales group to meet Customer Needs. Launch a new sales division focusing on customer needs (included large HMO/ PBM, Hospital and top tier Medical Groups). Drive Managed Care pull-though, sales/ managed care formulary decisions and increase Trust and Value proposition for Merck. Lead Adherence, Healthcare Disparity/HealthCare Literacy strategy and Cardiovascular Strategy. Lead a team of promotion marketing managers (solution designers). Expert in Managed Care and Healthcare environment/ policy.

As a Sales Executive, lead Managed Care Account negotiations, financial analysis and customer relationship. As a Marketing Executive, developed and executed segment strategy for HMO/ PRM and National Medicaid. Proven results in strategy, planning, and execution of preferred formulary status and pull-through resources to drive revenue within a sales line unit. Experience in forecasting, utilizing critical data, models, & research to formulate strategic plans in emerging Health Care segments.

Lead marketing & strategy for pharmacy/ wholesalers division. Managed pharmacy academic and professional relationship with national and local pharmacy organizations and schools of pharmacy. Established and lead a PharmD preceptor program for Merck Pharmacy & Academic Affairs. Lead continuing education programs and educational events for Merck.